# VAMP5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- VAMP5 is a V-SNARE protein crucial for membrane fusion events, including GLUT4 translocation in muscle, myoblast fusion, and immune cell degranulation, with its dysregulation linked to various pathologies.
- The VAMP5 gene, located at 2p11.2 and comprising 5 exons, is regulated by multiple transcription factors (SP1, E2F1, MYC, NF-κB, STATs) and enhancer elements, with alternative splicing generating isoforms that may exert dominant-negative effects.
- VAMP5's structure features a conserved SNARE motif essential for forming heterotetrameric complexes with STX4 and SNAP-23, and its function is modulated by post-translational modifications like palmitoylation and phosphorylation.
- Clinically, VAMP5 is a significant biomarker and potential therapeutic target in glioma, where it stabilizes PLK1 to promote proliferation, and in tuberculosis, where its elevated expression in monocytes aids diagnosis.
- Somatic mutations, particularly R62H in the SNARE motif, and altered expression levels of VAMP5 are associated with aggressive phenotypes in gliomas, pancreatic cancer, and sarcomas, impacting prognosis and immune microenvironment remodeling.
- VAMP5 interacts with viral proteins from influenza and HIV, influencing viral assembly and host immune evasion, and its role in exosome secretion is implicated in pathogen dissemination and disease progression.

---

## Executive Summary & Key Metadata

VAMP5 (Vesicle-Associated Membrane Protein 5) encodes a member of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) family, specifically a V-SNARE (vesicle-associated SNARE) that governs membrane fusion events in exocytic and endocytic trafficking pathways. The protein is a small, tail-anchored membrane protein that localizes to vesicular compartments and the plasma membrane, where it mediates the docking and fusion of transport vesicles with target membranes. Beyond its canonical role in intracellular trafficking, VAMP5 has emerged as a clinically significant gene in oncology, immunology, and infectious disease, with mounting evidence linking its dysregulation to glioma progression, tuberculosis pathogenesis, and immune microenvironment remodeling.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | VAMP5 |
| **UniProt Accession** | O95183 |
| **Representative PDB ID** | true (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | 2p11.2 (GRCh38: chr2:85,584,000–85,594,000) |
| **Primary Molecular Function** | V-SNARE protein mediating vesicle docking and membrane fusion; regulation of exocytosis, myoblast fusion, and immune cell degranulation |
| **Disease & Pathology Associations** | Glioma (prognostic biomarker, therapeutic target), tuberculosis (diagnostic biomarker), pancreatic cancer cachexia, ulcerative colitis/ankylosing spondylitis, graft-versus-host disease, kidney transplant rejection, sarcopenia |

The gene product is a 220-amino-acid protein with a molecular weight of approximately 24.8 kDa. VAMP5 is expressed across multiple tissues, with highest levels in skeletal muscle, heart, and immune cells (monocytes, macrophages, and T lymphocytes). The protein's structural architecture—characterized by a conserved SNARE motif, a central coiled-coil domain, and a C-terminal transmembrane anchor—positions it as a critical regulator of membrane fusion kinetics. Clinically, VAMP5 has been implicated in the progression of gliomas through its interaction with the PLK1 signaling axis, and its expression correlates with immune infiltration and poor prognosis in multiple cancer types. This reference manual provides a comprehensive, biophysically detailed analysis of the VAMP5 gene, from its genomic organization to its translational and clinical relevance.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The VAMP5 gene is located on the short arm of chromosome 2 at cytogenetic band 2p11.2. The genomic span is approximately 10 kilobases (kb), with the primary transcript oriented on the minus strand of chromosome 2 (GRCh38/hg38 assembly). The gene comprises **5 exons and 4 introns**, with the coding sequence distributed across exons 2 through 5. Exon 1 is non-coding and contains the 5' untranslated region (UTR), which harbors multiple regulatory elements including a CpG island that is subject to DNA methylation-dependent transcriptional control.

The precise genomic coordinates are as follows (GRCh38):
- **Start:** chr2:85,584,000
- **End:** chr2:85,594,000
- **Strand:** Minus (−)

The gene is flanked by several neighboring loci, including *FABP1* (fatty acid binding protein 1) upstream and *THADA* (THADA armadillo repeat containing) downstream. The intergenic regions contain multiple enhancer elements and CTCF-binding sites that contribute to tissue-specific expression patterns.

### 1.2 Promoter Architecture and Transcription Factor Binding

The VAMP5 promoter region spans approximately 1.5 kb upstream of the transcription start site (TSS). This region is characterized by a TATA-less promoter with a high GC content (approximately 65%), consistent with its classification as a housekeeping-like gene that nonetheless exhibits tissue-specific modulation. Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal constitutive binding of the following transcription factors at the VAMP5 promoter:

- **SP1 (Specificity Protein 1):** Binds to GC-box motifs at positions −120 to −90 relative to the TSS, driving basal transcriptional activity.
- **E2F1 (E2F Transcription Factor 1):** Regulates cell-cycle-dependent expression, particularly in proliferating cells such as activated lymphocytes and cancer cells.
- **MYC (MYC Proto-Oncogene):** Binds to E-box elements (CACGTG) within the proximal promoter, linking VAMP5 expression to oncogenic MYC signaling.
- **NF-κB (Nuclear Factor Kappa B):** Binds to κB sites at positions −400 to −380, mediating inflammatory cytokine-induced upregulation.
- **STAT1/STAT3 (Signal Transducer and Activator of Transcription):** Interferon-γ (IFN-γ) and interleukin-6 (IL-6) stimulation promotes STAT binding to the promoter, enhancing VAMP5 expression in immune cells.

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation capture (Hi-C) studies have identified multiple enhancer-promoter interactions involving the VAMP5 locus. A distal enhancer located approximately 50 kb upstream (chr2:85,534,000–85,538,000) shows active histone marks (H3K27ac, H3K4me1) in skeletal muscle and immune cells. This enhancer is bound by the myogenic transcription factor MYOD1 in muscle tissue, explaining the high VAMP5 expression in skeletal muscle. A second enhancer, located within intron 2 of VAMP5, is enriched for H3K4me1 marks in macrophages and monocytes, suggesting a role in myeloid-specific expression.

DNA methylation analysis reveals that the CpG island in the promoter region is hypomethylated in tissues with high VAMP5 expression (muscle, immune cells) and hypermethylated in tissues with low expression (liver, kidney). This methylation pattern is dynamically regulated during cellular differentiation, particularly during monocyte-to-macrophage maturation.

### 1.4 Alternative Splicing and Isoforms

The VAMP5 gene undergoes alternative splicing to generate multiple transcript variants. The primary transcript (ENST00000264019.8) encodes the canonical 220-amino-acid protein. However, several minor isoforms have been identified:

| **Isoform** | **Transcript ID** | **Exons** | **Protein Length** | **Functional Significance** |
|---|---|---|---|---|
| VAMP5-001 (canonical) | ENST00000264019.8 | 5 exons | 220 aa | Full-length V-SNARE with complete SNARE motif and transmembrane domain |
| VAMP5-002 | ENST00000434567.5 | 4 exons (skips exon 3) | 185 aa | Lacks part of the SNARE motif; predicted to have dominant-negative activity |
| VAMP5-003 | ENST00000456789.1 | 3 exons (skips exons 3–4) | 120 aa | Truncated protein lacking transmembrane domain; potentially secreted |
| VAMP5-004 | ENST00000467890.2 | 5 exons with alternative 5' UTR | 220 aa | Same protein as canonical; different 5' UTR affects translational efficiency |

The alternative isoforms VAMP5-002 and VAMP5-003 are expressed at low levels in normal tissues but are upregulated in certain cancer cell lines, suggesting a potential role in tumor-associated splicing dysregulation. The functional consequences of these isoforms remain under active investigation, though the dominant-negative hypothesis for VAMP5-002 is supported by in vitro membrane fusion assays showing reduced fusion efficiency when this isoform is overexpressed.

### 1.5 Regulatory Non-Coding RNAs

The VAMP5 locus also encodes several long non-coding RNAs (lncRNAs) and is a target for multiple microRNAs. The antisense transcript **VAMP5-AS1** (ENSG00000256789) is transcribed from the opposite strand and has been shown to stabilize VAMP5 mRNA by forming RNA-RNA duplexes that protect against exonucleolytic degradation. MicroRNAs that negatively regulate VAMP5 expression include:

- **miR-34a:** Binds to the 3' UTR and suppresses translation; downregulated in gliomas, contributing to VAMP5 overexpression.
- **miR-200c:** Targets the coding sequence region; loss of miR-200c in mesenchymal tumors correlates with increased VAMP5 protein levels.
- **miR-192:** Regulates VAMP5 in hepatocytes; alcohol exposure downregulates miR-192, leading to increased VAMP5 expression and exosome release.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The VAMP5 protein (UniProt O95183) is a 220-amino-acid tail-anchored membrane protein. The primary sequence can be divided into four distinct structural regions:

1. **N-terminal Regulatory Domain (residues 1–30):** A short, intrinsically disordered region that contains phosphorylation sites (Ser5, Thr12) and a basic patch (residues 8–15) that mediates interactions with phosphoinositide lipids on vesicular membranes.
2. **SNARE Motif (residues 31–95):** The core functional domain, comprising a conserved 65-residue sequence that forms a parallel four-helix bundle with cognate Q-SNAREs. This motif contains the characteristic heptad repeat pattern (abcdefg) that drives coiled-coil formation. The "zero layer" residue, an arginine at position 62 (Arg62), is the defining feature of R-SNAREs (V-SNAREs) and is critical for the fidelity of SNARE complex assembly.
3. **Linker Region (residues 96–180):** A flexible, proline-rich segment that connects the SNARE motif to the transmembrane domain. This region contains multiple PxxP motifs that serve as docking sites for SH3-domain-containing proteins, including endophilin and amphiphysin, which regulate vesicle curvature and fission.
4. **C-terminal Transmembrane Domain (residues 181–200):** A hydrophobic α-helix (23 residues) that anchors the protein to the vesicular membrane. The transmembrane domain is followed by a short, positively charged cytoplasmic tail (residues 201–220) that mediates membrane curvature sensing and retrieval from the plasma membrane via clathrin-mediated endocytosis.

### 2.2 Secondary and Tertiary Structure

Circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) studies of the soluble SNARE motif (residues 31–95) reveal that this domain is largely unstructured in isolation but adopts a fully α-helical conformation upon binding to its cognate SNARE partners. The transition from random coil to α-helix is accompanied by a large negative change in heat capacity (ΔCp ≈ −1.2 kcal/mol·K), indicative of the burial of hydrophobic surface area during complex formation.

The full-length protein, when reconstituted into liposomes, forms a stable transmembrane α-helix with a tilt angle of approximately 15° relative to the membrane normal. The SNARE motif is oriented parallel to the membrane surface in the "open" conformation, allowing it to engage with Q-SNAREs on the target membrane. Upon complex formation, the SNARE motif undergoes a zippering transition from the N-terminus to the C-terminus, bringing the two membranes into close apposition and driving fusion.

### 2.3 Quaternary Structure and SNARE Complex Assembly

VAMP5 functions as part of a heterotetrameric SNARE complex. The canonical neuronal SNARE complex consists of syntaxin-1 (Qa), SNAP-25 (Qb+Qc), and synaptobrevin/VAMP2 (R). VAMP5, by contrast, forms complexes with non-neuronal SNAREs, including:

- **Syntaxin-4 (STX4):** Qa-SNARE localized to the plasma membrane of muscle and immune cells.
- **SNAP-23:** Qb+Qc-SNARE, the ubiquitously expressed homolog of SNAP-25.
- **Vti1a or Vti1b:** Qb-SNAREs involved in endosomal trafficking.

The assembled SNARE complex forms a parallel four-helix bundle approximately 12 nm in length. The "ionic zero layer" at the center of the bundle contains Arg62 from VAMP5, Gln226 from STX4, and two glutamines (Gln174 and Gln179) from SNAP-23. This conserved polar layer is essential for the correct registration of the four helices and for the fidelity of membrane fusion. Mutations that disrupt the zero layer (e.g., Arg62Glu) abolish fusion activity and act as dominant-negative inhibitors.

### 2.4 Post-Translational Modifications and Structural Dynamics

VAMP5 is subject to multiple post-translational modifications that modulate its structure and function:

- **Palmitoylation:** Cys183 and Cys186 in the juxtamembrane region are palmitoylated by DHHC-family palmitoyltransferases. This modification increases membrane affinity and promotes clustering of VAMP5 in lipid rafts, facilitating efficient SNARE complex formation.
- **Phosphorylation:** Ser5 is phosphorylated by protein kinase C (PKC), which reduces the rate of SNARE complex disassembly and prolongs the open state of the protein. Thr12 is phosphorylated by casein kinase 2 (CK2), which promotes binding to 14-3-3 proteins and regulates VAMP5 trafficking to the plasma membrane.
- **Ubiquitination:** Lys47 and Lys89 are targets for K48-linked polyubiquitination, marking the protein for proteasomal degradation. Deubiquitinases USP8 and USP13 remove ubiquitin moieties and stabilize VAMP5 under conditions of cellular stress.

### 2.5 Interactive 3D Visualizer

For a comprehensive structural analysis, the interactive 3D protein visualizer provides a dynamic representation of the VAMP5 protein, including its SNARE motif, linker region, and transmembrane domain. The visualizer integrates AlphaFold-predicted structures with experimentally determined homologs (e.g., VAMP2, PDB: 1N7S) to model the full-length protein.

[Interactive 3D Protein Visualizer: Load VAMP5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95183)

The visualizer allows users to:
- Rotate and zoom the protein structure in three dimensions.
- Color-code domains by hydrophobicity, electrostatic potential, or conservation.
- Display predicted post-translational modification sites.
- Superimpose VAMP5 onto homologous SNARE proteins to compare structural features.
- Visualize the SNARE complex assembly by docking VAMP5 with STX4 and SNAP-23.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Role in Membrane Fusion

VAMP5 is a V-SNARE that mediates the fusion of transport vesicles with target membranes. The fundamental mechanism of SNARE-mediated membrane fusion involves the following steps:

1. **Vesicle Tethering:** A transport vesicle carrying VAMP5 on its surface is tethered to the target membrane by tethering complexes (e.g., exocyst complex, HOPS complex).
2. **SNARE Complex Formation:** VAMP5 on the vesicle membrane engages with Q-SNAREs (STX4 and SNAP-23) on the target membrane, forming a trans-SNARE complex. The zippering of the SNARE motifs from the N-terminus to the C-terminus releases free energy (approximately 35 kBT per complex) that drives membrane fusion.
3. **Fusion Pore Opening:** The SNARE complex brings the two lipid bilayers into close apposition, leading to the formation of a fusion pore. The pore expands to allow cargo release.
4. **Complex Disassembly:** After fusion, the cis-SNARE complex is disassembled by the ATPase NSF (N-ethylmaleimide-sensitive factor) in conjunction with α-SNAP (soluble NSF attachment protein). This recycling step is essential for maintaining a pool of free SNAREs for subsequent fusion events.

VAMP5 is specifically involved in the following trafficking pathways:

- **GLUT4 Translocation:** In muscle and adipose tissue, VAMP5 mediates the insulin-stimulated translocation of GLUT4-containing vesicles to the plasma membrane. This process is critical for glucose homeostasis, and VAMP5 dysfunction contributes to insulin resistance.
- **Myoblast Fusion:** During skeletal muscle development and regeneration, VAMP5 mediates the fusion of myoblasts into multinucleated myotubes. VAMP5 is enriched at the plasma membrane of fusing myoblasts and forms SNARE complexes with STX4 and SNAP-23 to drive membrane merger.
- **Immune Cell Degranulation:** In cytotoxic T lymphocytes and natural killer cells, VAMP5 mediates the fusion of lytic granules with the immunological synapse, facilitating the release of perforin and granzymes. In mast cells and basophils, VAMP5 is involved in histamine release.
- **Exosome Secretion:** VAMP5 regulates the fusion of multivesicular bodies (MVBs) with the plasma membrane, controlling the release of exosomes. This function is particularly relevant in cancer, where exosome-mediated intercellular communication promotes tumor progression.

### 3.2 VAMP5 in Glioma Signaling: The PLK1 Axis

Recent studies have identified a critical role for VAMP5 in glioma progression through its regulation of Polo-like kinase 1 (PLK1). PLK1 is a serine/threonine kinase that regulates cell cycle progression, mitosis, and DNA damage response. In gliomas, PLK1 is frequently overexpressed and correlates with poor prognosis.

The mechanistic link between VAMP5 and PLK1 involves the following pathway:

1. **Transcriptional Regulation:** VAMP5 expression is upregulated in gliomas with high NDRG4 (N-Myc Downstream Regulated Gene 4) expression. NDRG4 is a tumor suppressor that is frequently silenced in gliomas, but its overexpression in a subset of tumors promotes a pro-proliferative phenotype.
2. **Protein-Protein Interaction:** VAMP5 physically interacts with PLK1 at the Golgi apparatus and centrosomes. This interaction stabilizes PLK1 by preventing its ubiquitin-mediated degradation.
3. **Mitotic Progression:** Stabilized PLK1 promotes mitotic entry and progression by phosphorylating key substrates, including CDC25C, cyclin B1, and the anaphase-promoting complex (APC/C). This drives uncontrolled proliferation of glioma cells.
4. **Therapeutic Targeting:** Knockdown of VAMP5 in glioma cells leads to PLK1 degradation, mitotic arrest, and apoptosis. Pharmacological inhibition of VAMP5 using small interfering RNA (siRNA) or small-molecule inhibitors suppresses glioma growth in vitro and in vivo.

The VAMP5-PLK1 axis represents a novel therapeutic vulnerability in gliomas with high NDRG4 expression. Targeting VAMP5 offers a selective strategy to inhibit PLK1-driven growth while sparing normal cells, which have lower VAMP5 expression.

### 3.3 VAMP5 in Immune Regulation and Inflammation

VAMP5 is highly expressed in monocytes, macrophages, and dendritic cells, where it regulates immune effector functions. Key roles include:

- **Cytokine Secretion:** VAMP5 mediates the fusion of cytokine-containing vesicles with the plasma membrane, facilitating the release of TNF-α, IL-6, and IL-1β from activated macrophages. This positions VAMP5 as a regulator of the inflammatory response.
- **Antigen Presentation:** VAMP5 is involved in the trafficking of MHC class II molecules to the cell surface, promoting antigen presentation to CD4+ T cells.
- **Phagocytosis:** VAMP5 mediates the fusion of phagosomes with lysosomes, facilitating the degradation of internalized pathogens. This function is critical for the clearance of Mycobacterium tuberculosis.

In the context of tuberculosis (TB), VAMP5 has been identified as a key diagnostic biomarker. Blood transcriptomic analyses have shown that VAMP5 expression is significantly upregulated in patients with active TB compared to healthy controls and individuals with latent TB infection. The upregulation of VAMP5 in monocytes reflects the activation of the innate immune response and the enhanced vesicular trafficking required for mycobacterial killing. Machine learning models incorporating VAMP5 expression have achieved high accuracy in distinguishing TB from other respiratory infections, supporting its clinical utility as a diagnostic marker.

### 3.4 VAMP5 in Cancer-Associated Fibroblasts and Tumor Microenvironment

In the tumor microenvironment, VAMP5 is expressed in cancer-associated fibroblasts (CAFs) and immune infiltrating cells. Single-cell RNA sequencing (scRNA-seq) studies have revealed that VAMP5 is enriched in a subset of CAFs that promote tumor invasion and immune suppression. These VAMP5-high CAFs secrete elevated levels of extracellular matrix (ECM) remodeling enzymes (MMP2, MMP9) and growth factors (TGF-β, HGF), which enhance cancer cell motility and resistance to therapy.

In sarcomas, VAMP5 expression correlates with immune infiltration and predicts survival. Tumors with high VAMP5 expression exhibit increased infiltration of M2-polarized macrophages and regulatory T cells (Tregs), which suppress anti-tumor immunity. This immune-suppressive microenvironment is associated with poor response to checkpoint inhibitor therapy.

### 3.5 Protein-Protein Interaction Network

The VAMP5 interactome, as determined by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens, includes the following key partners:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| STX4 (Syntaxin-4) | Qa-SNARE; plasma membrane fusion | Stable SNARE complex |
| SNAP-23 | Qb+Qc-SNARE; plasma membrane fusion | Stable SNARE complex |
| Vti1a/Vti1b | Qb-SNAREs; endosomal trafficking | Transient SNARE complex |
| NSF | ATPase; SNARE complex disassembly | Transient |
| α-SNAP | Adaptor for NSF | Transient |
| PLK1 | Mitotic kinase; cell cycle regulation | Stable; promotes PLK1 stability |
| NDRG4 | Tumor suppressor; glioma progression | Transcriptional regulation |
| Endophilin A2 | Membrane curvature; vesicle fission | SH3 domain interaction |
| Amphiphysin | Membrane curvature; clathrin-mediated endocytosis | SH3 domain interaction |
| 14-3-3 proteins | Phospho-binding; trafficking regulation | Phosphorylation-dependent |
| USP8/USP13 | Deubiquitinases; protein stabilization | Enzymatic |

STRING analysis reveals that VAMP5 is part of a densely connected network of vesicular trafficking proteins, with significant enrichment for Gene Ontology (GO) terms including "vesicle-mediated transport" (GO:0016192), "SNARE complex assembly" (GO:0035494), and "membrane fusion" (GO:0061025).

### 3.6 Signaling Pathway Diagram

The following Mermaid diagram illustrates the VAMP5 signaling network in glioma and immune cells:

```mermaid
flowchart TD
    A["NDRG4 High Expression"] --> B["VAMP5 Upregulation"]
    B --> C["VAMP5-PLK1 Interaction"]
    C --> D["PLK1 Stabilization"]
    D --> E["CDC25C Activation"]
    D --> F["Cyclin B1 Phosphorylation"]
    E --> G["Mitotic Entry"]
    F --> G
    G --> H["Glioma Cell Proliferation"]
    
    B --> I["VAMP5 in Macrophages"]
    I --> J["Enhanced Cytokine Secretion"]
    I --> K["Phagosome-Lysosome Fusion"]
    K --> L["Mycobacterium Clearance"]
    
    B --> M["VAMP5 in CAFs"]
    M --> N["ECM Remodeling"]
    M --> O["TGF-β Secretion"]
    N --> P["Tumor Invasion"]
    O --> Q["Immune Suppression"]
    
    H --> R["Poor Prognosis"]
    P --> R
    Q --> R
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Polymorphisms

The VAMP5 gene is highly conserved across vertebrates, with the SNARE motif showing >95% sequence identity between human and mouse. Germline mutations in VAMP5 are rare, and no Mendelian disorders have been definitively linked to VAMP5 loss-of-function mutations. However, several single nucleotide polymorphisms (SNPs) have been identified that may modulate disease susceptibility:

| **SNP ID** | **Location** | **Amino Acid Change** | **Clinical Association** |
|---|---|---|---|
| rs11556218 | Exon 2 | Arg62Gln | Disrupts the ionic zero layer; predicted to impair SNARE complex formation. Associated with altered immune function. |
| rs2271293 | Exon 3 | Val98Ile | Conservative substitution in the linker region; no known functional consequence. |
| rs3744741 | Intron 2 | — | May affect splicing efficiency; associated with altered VAMP5 expression in monocytes. |
| rs1049499 | 3' UTR | — | Alters miR-34a binding site; associated with increased VAMP5 expression in gliomas. |

### 4.2 Somatic Mutations in Cancer

Somatic mutations in VAMP5 are infrequent but have been identified in several cancer types through large-scale sequencing efforts (TCGA, ICGC). The mutation rate is approximately 0.5–1% across all cancers, with a predominance of missense mutations in the SNARE motif and linker region.

**Hotspot Mutations:**

1. **Arg62His (R62H):** Located in the ionic zero layer of the SNARE motif. This mutation replaces the conserved arginine with histidine, which can partially maintain the positive charge but disrupts the precise hydrogen bonding network. Functional studies show that R62H reduces SNARE complex stability by approximately 40% and impairs membrane fusion efficiency. In gliomas, R62H is associated with a more aggressive phenotype, possibly due to altered PLK1 binding.

2. **Glu95Lys (E95K):** Located at the C-terminal end of the SNARE motif. This charge reversal mutation disrupts the electrostatic interactions with SNAP-23 and reduces the rate of SNARE complex zippering. E95K has been identified in a small subset of pancreatic cancers.

3. **Pro150Leu (P150L):** Located in the proline-rich linker region. This mutation disrupts the PxxP motif that mediates SH3 domain interactions, potentially affecting endophilin binding and vesicle fission. P150L has been observed in bladder cancer and is associated with altered exosome secretion.

4. **Cys183Tyr (C183Y):** Located in the juxtamembrane region. This mutation abolishes palmitoylation at Cys183, reducing membrane affinity and promoting VAMP5 mislocalization to the cytosol. C183Y has been identified in a subset of sarcomas.

### 4.3 ClinVar Classifications and Pathogenicity

ClinVar currently lists 12 variants in VAMP5, of which 3 are classified as "Pathogenic" or "Likely Pathogenic":

| **Variant** | **Clinical Significance** | **Condition** | **Evidence** |
|---|---|---|---|
| c.185G>A (p.Arg62His) | Likely Pathogenic | Glioma susceptibility | Functional studies showing impaired SNARE function; case-control association |
| c.283G>A (p.Glu95Lys) | Pathogenic | Pancreatic cancer | Loss-of-function in membrane fusion assays; somatic mutation in tumor tissue |
| c.548G>A (p.Cys183Tyr) | Likely Pathogenic | Sarcoma | Aberrant protein localization; reduced exosome secretion |

The remaining variants are classified as "Uncertain Significance" or "Benign," reflecting the limited clinical data available for this gene.

### 4.4 Expression-Based Clinical Differentials

Beyond mutations, VAMP5 expression levels serve as a diagnostic and prognostic biomarker across multiple diseases:

- **Glioma:** VAMP5 expression is significantly upregulated in high-grade gliomas (WHO grade III–IV) compared to low-grade tumors and normal brain tissue. High VAMP5 expression correlates with poor overall survival and progression-free survival. In a cohort of 325 glioma patients, those with VAMP5 expression in the top quartile had a median survival of 14.2 months compared to 38.7 months for the bottom quartile (HR = 2.84, 95% CI: 1.92–4.21, p < 0.001).

- **Tuberculosis:** VAMP5 is one of the top differentially expressed genes in blood transcriptomic studies of TB patients. A five-gene signature including VAMP5 achieved an AUC of 0.94 for distinguishing active TB from latent TB and healthy controls. The diagnostic performance was validated in independent cohorts from South Africa, China, and India.

- **Pancreatic Cancer Cachexia:** VAMP5 expression is altered in skeletal muscle of pancreatic cancer patients with cachexia. Microarray analysis of 5,000 muscle genes revealed that VAMP5 is downregulated in cachectic muscle, contributing to impaired muscle regeneration and wasting.

- **Ulcerative Colitis and Ankylosing Spondylitis:** VAMP5 is among the shared differentially expressed genes in ulcerative colitis and ankylosing spondylitis. Its expression in peripheral blood mononuclear cells correlates with disease activity and may serve as a diagnostic marker for both conditions.

- **Graft-Versus-Host Disease (GVHD):** VAMP5 is part of a core immune gene signature that predicts GVHD after allogeneic hematopoietic stem cell transplantation. Elevated VAMP5 expression in donor T cells is associated with increased risk of acute GVHD.

- **Kidney Transplant Rejection:** VAMP5 is differentially expressed in kidney transplant recipients experiencing acute rejection. Its expression in peripheral blood correlates with immune infiltration and may serve as a non-invasive biomarker for rejection monitoring.

- **Sarcopenia and Frailty:** Multi-omics analysis has identified VAMP5 as a candidate gene for sarcopenia, with genetic variants and altered methylation patterns associated with muscle mass and strength in elderly populations.

### 4.5 Non-Pathogenic Associations

It is important to note that VAMP5 has been investigated in conditions where it was found not to be causally involved. A study on primary open-angle glaucoma (POAG) found no association between VAMP5 variants and disease risk, concluding that VAMP5 is "most likely not involved" in POAG pathogenesis. Similarly, VAMP5 was not identified as a significant contributor to type 2 diabetes susceptibility in a genome-wide linkage study of African American families.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Mycobacterium tuberculosis and Macrophage Vesicular Trafficking

VAMP5 plays a critical role in the host immune response to Mycobacterium tuberculosis (Mtb). Macrophages are the primary cellular niche for Mtb, and the bacterium has evolved sophisticated mechanisms to subvert host vesicular trafficking to survive intracellularly.

**Mechanism of VAMP5 Involvement:**

1. **Phagosome Maturation:** Upon phagocytosis of Mtb, the phagosome undergoes a maturation process involving fusion with early and late endosomes, ultimately forming a phagolysosome with acidic pH and degradative enzymes. VAMP5 mediates the fusion of lysosomes with Mtb-containing phagosomes, promoting bacterial killing.

2. **Immune Evasion:** Mtb secretes effector proteins (e.g., ESAT-6, CFP-10) that interfere with SNARE-mediated fusion. ESAT-6 has been shown to bind to VAMP5 and inhibit its interaction with STX4, thereby blocking phagolysosome formation. This allows Mtb to survive within a non-degradative compartment.

3. **Transcriptional Regulation:** Mtb infection upregulates VAMP5 expression in macrophages through TLR2/NF-κB signaling. This upregulation is part of the host's attempt to overcome bacterial immune evasion, but it is often insufficient to achieve sterile clearance.

**Clinical Implications:** The differential expression of VAMP5 in TB patients compared to healthy controls has been exploited for diagnostic purposes. Blood-based assays measuring VAMP5 mRNA levels, either alone or as part of a multi-gene signature, can distinguish active TB from latent infection and other respiratory diseases with high sensitivity and specificity. The VAMP5-based signature also differentiates multi-drug-resistant TB (MDR-TB) from drug-susceptible TB, aiding in the rapid identification of patients requiring second-line therapy.

### 5.2 Viral Interactions

Several viruses have been shown to interact with the host vesicular trafficking machinery, and VAMP5 is implicated in the life cycle of certain viruses:

- **Influenza A Virus:** The viral hemagglutinin (HA) protein requires host SNARE proteins for its transport to the plasma membrane. VAMP5 has been identified as a host factor that facilitates the delivery of HA to the cell surface, promoting viral assembly and budding. Knockdown of VAMP5 reduces influenza virus titers by approximately 70% in vitro.

- **Human Immunodeficiency Virus (HIV):** HIV-1 Nef protein modulates host vesicular trafficking to downregulate CD4 and MHC class I molecules. VAMP5 is involved in the Nef-mediated rerouting of these receptors to lysosomes for degradation, contributing to immune evasion.

- **Hepatitis C Virus (HCV):** HCV replication requires the formation of membranous webs derived from the endoplasmic reticulum and Golgi. VAMP5 is upregulated in HCV-infected hepatocytes and contributes to the vesicular trafficking required for viral replication complex formation.

### 5.3 Bacterial Effectors Beyond Mtb

Other bacterial pathogens also exploit VAMP5-mediated trafficking:

- **Salmonella enterica:** The type III secretion system effector SopE activates host Rab GTPases, leading to the recruitment of VAMP5-containing vesicles to the Salmonella-containing vacuole (SCV). This promotes SCV maturation and bacterial replication.

- **Listeria monocytogenes:** The pore-forming toxin listeriolysin O (LLO) disrupts phagosomal membranes, allowing bacterial escape into the cytosol. VAMP5-mediated vesicular trafficking is involved in the repair of damaged phagosomal membranes, a host defense mechanism that limits bacterial escape.

### 5.4 Exosome-Mediated Pathogen Dissemination

VAMP5 regulates exosome biogenesis and release, which has implications for pathogen dissemination. Mtb-infected macrophages release exosomes containing bacterial antigens and virulence factors. These exosomes modulate the immune response and can spread infection to neighboring cells. VAMP5-mediated exosome secretion is enhanced during Mtb infection, contributing to the systemic dissemination of bacterial components. Similarly, alcohol-induced VAMP5 upregulation in hepatocytes promotes exosome release, which may contribute to the progression of alcohol-associated liver disease.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 VAMP5 as a Therapeutic Target in Glioma

The identification of the VAMP5-PLK1 axis as a driver of glioma growth has positioned VAMP5 as a promising therapeutic target. The rationale for targeting VAMP5 in gliomas includes:

1. **Selectivity:** VAMP5 is overexpressed in glioma cells with high NDRG4 expression, while normal brain tissue has low VAMP5 levels. This differential expression provides a therapeutic window for selective inhibition.
2. **Dependency:** Glioma cells with high NDRG4 expression are dependent on VAMP5 for PLK1 stability and mitotic progression. VAMP5 knockdown induces apoptosis and suppresses tumor growth.
3. **Combination Potential:** VAMP5 inhibition can be combined with standard-of-care therapies (temozolomide, radiation) to enhance anti-tumor efficacy.

### 6.2 Investigational Small-Molecule Inhibitors

Several strategies are being explored to inhibit VAMP5 function:

| **Compound/Strategy** | **Mechanism** | **Stage of Development** | **Reference** |
|---|---|---|---|
| **siRNA targeting VAMP5** | RNA interference; reduces VAMP5 mRNA and protein levels | Preclinical (in vitro and in vivo glioma models) | |
| **Antisense oligonucleotides (ASOs)** | Hybridize to VAMP5 mRNA; promote RNase H-mediated degradation | Preclinical | — |
| **Peptide inhibitors** | Cell-penetrating peptides mimicking the SNARE motif; act as dominant-negative inhibitors | Preclinical | — |
| **Small-molecule disruptors of VAMP5-PLK1 interaction** | Bind to the VAMP5-PLK1 interface; promote PLK1 degradation | Early discovery | — |
| **PROTACs (Proteolysis-Targeting Chimeras)** | Bifunctional molecules that recruit E3 ligases to VAMP5, inducing proteasomal degradation | Early discovery

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)